Stock Research for CRIS

CRIS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CRIS Stock Chart & Research Data

The CRIS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRIS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CRIS Due diligence Resources & Stock Charts

The CRIS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CRIS Detailed Price Forecast - CNN Money CNN View CRIS Detailed Summary - Google Finance
Yahoo View CRIS Detailed Summary - Yahoo! Finance Zacks View CRIS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CRIS Trends & Analysis - Trade-Ideas Barrons View CRIS Major Holders - Barrons
NASDAQ View CRIS Call Transcripts - NASDAQ Seeking View CRIS Breaking News & Analysis - Seeking Alpha
Spotlight View CRIS Annual Report - CompanySpotlight.com OTC Report View CRIS OTC Short Report - OTCShortReport.com
TradeKing View CRIS Fundamentals - TradeKing Charts View CRIS SEC Filings - Bar Chart
WSJ View Historical Prices for CRIS - The WSJ Morningstar View Performance/Total Return for CRIS - Morningstar
MarketWatch View the Analyst Estimates for CRIS - MarketWatch CNBC View the Earnings History for CRIS - CNBC
StockMarketWatch View the CRIS Earnings - StockMarketWatch MacroAxis View CRIS Buy or Sell Recommendations - MacroAxis
Bullish View the CRIS Bullish Patterns - American Bulls Short Pains View CRIS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CRIS Stock Mentions - StockTwits PennyStocks View CRIS Stock Mentions - PennyStockTweets
Twitter View CRIS Stock Mentions - Twitter Invest Hub View CRIS Investment Forum News - Investor Hub
Yahoo View CRIS Stock Mentions - Yahoo! Message Board Seeking Alpha View CRIS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CRIS - SECform4.com Insider Cow View Insider Transactions for CRIS - Insider Cow
CNBC View CRIS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CRIS - OTC Markets
Yahoo View Insider Transactions for CRIS - Yahoo! Finance NASDAQ View Institutional Holdings for CRIS - NASDAQ


Stock Charts

FinViz View CRIS Stock Insight & Charts - FinViz.com StockCharts View CRIS Investment Charts - StockCharts.com
BarChart View CRIS Stock Overview & Charts - BarChart Trading View View CRIS User Generated Charts - Trading View




Latest Financial News for CRIS


Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference
Posted on Monday March 04, 2019

LEXINGTON, Mass. , March 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...


Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference
Posted on Monday February 04, 2019

LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...


Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
Posted on Tuesday January 29, 2019

Is (CRIS) Outperforming Other Medical Stocks This Year?


First Mesothelioma Patient Dosed in CA-170 Study
Posted on Thursday January 24, 2019

LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.